AML‐RAM with CBFA2T3::GLIS2 fusion showed a trend but no significant difference in OS and EFS as compared to fusion‐negative patients (albeit lack of significance, p = 0.05) (Figure 2 ).
← all excerpts
Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56-positive acute leukemias.
1
—
—